Tarsus Pharmaceuticals (TARS) Non Operating Income (2019 - 2026)

Tarsus Pharmaceuticals' Non Operating Income history runs 8 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 29.91% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $7.0 million, a 64.78% increase from a year earlier, with the FY2025 full-year figure at $6.6 million, up 31.8% from the prior year.
• Non Operating Income fell to $1.5 million in Q1 2026 per TARS's latest filing, from $1.7 million in the prior quarter.
• Across five years, Non Operating Income topped out at $2.5 million in Q4 2023 and bottomed at -$716000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $1.5 million (2026), against an average of $1.2 million.
• Across the five-year window, Non Operating Income slumped 7514.29% in 2022 and soared 15266.67% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $1.5 million in 2022, then soared by 74.28% to $2.5 million in 2023, then slumped by 48.67% to $1.3 million in 2024, then grew by 27.06% to $1.7 million in 2025, then decreased by 9.33% to $1.5 million in 2026.
• Per Business Quant, the three latest TARS Non Operating Income figures stand at $1.5 million (Q1 2026), $1.7 million (Q4 2025), and $1.9 million (Q3 2025).